Myeloid Therapeutics

About

Myeloid Therapeutics is a clinical-stage immunology company based in Cambridge, Massachusetts, founded in 2019. The company focuses on developing mRNA-based immunotherapies that target and activate myeloid cells in solid tumors to enhance anti-tumor immunity. By integrating advanced methods from immunology, genetics, cell biology, and protein science, Myeloid Therapeutics aims to improve patient outcomes in oncology. The company's lead product, MT-302, is a Phase 1 mRNA-CAR therapy designed to program myeloid cells to target specific cancer cells. Myeloid Therapeutics is driven by a team of experts in various fields, including oncology and immunology, who contribute to its innovative approach. The company is looking forward to significant updates, including Phase 1 data for MT-302, expected in the second half of 2025, which will provide insights into the product's efficacy and safety.